- Home
- ANNX vs FRST Comparison
ANNX vs FRST Comparison
Compare ANNX & FRST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- FRST
- Stock Information
- Founded
- ANNX 2011
- FRST 2004
- Country
- ANNX United States
- FRST United States
- Employees
- ANNX N/A
- FRST N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- FRST Major Banks
- Sector
- ANNX Health Care
- FRST Finance
- Exchange
- ANNX Nasdaq
- FRST Nasdaq
- Market Cap
- ANNX 263.3M
- FRST 265.8M
- IPO Year
- ANNX 2020
- FRST 2006
- Fundamental
- Price
- ANNX $2.56
- FRST $11.17
- Analyst Decision
- ANNX Strong Buy
- FRST Buy
- Analyst Count
- ANNX 4
- FRST 1
- Target Price
- ANNX $12.50
- FRST $420.00
- AVG Volume (30 Days)
- ANNX 1.8M
- FRST 84.6K
- Earning Date
- ANNX 08-11-2025
- FRST 07-24-2025
- Dividend Yield
- ANNX N/A
- FRST 3.59%
- EPS Growth
- ANNX N/A
- FRST N/A
- EPS
- ANNX N/A
- FRST 0.16
- Revenue
- ANNX N/A
- FRST $125,133,000.00
- Revenue This Year
- ANNX N/A
- FRST $21.33
- Revenue Next Year
- ANNX N/A
- FRST $12.77
- P/E Ratio
- ANNX N/A
- FRST $69.48
- Revenue Growth
- ANNX N/A
- FRST 22.34
- 52 Week Low
- ANNX $1.29
- FRST $7.59
- 52 Week High
- ANNX $7.85
- FRST $13.52
- Technical
- Relative Strength Index (RSI)
- ANNX 54.40
- FRST 71.92
- Support Level
- ANNX $1.85
- FRST $10.40
- Resistance Level
- ANNX $2.97
- FRST $11.41
- Average True Range (ATR)
- ANNX 0.27
- FRST 0.25
- MACD
- ANNX 0.00
- FRST 0.04
- Stochastic Oscillator
- ANNX 60.32
- FRST 92.00
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About FRST Primis Financial Corp.
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. Primis Bank offers a broad range of deposit products, including checking (NOW), savings, money market accounts, and certificates of deposit. Its operating segments are Primis Mortgage, Primis Bank, and Other.